ReviewJournal of the advanced practitioner in oncology
Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies.
Review in Journal of the advanced practitioner in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Trial
- Article
- Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- An Overview of the Management of Electrolyte Emergencies and Imbalances in Cancer Patients.Journal of the advanced practitioner in oncology · 2025Review
- Article
- Tumour lysis syndrome.Nature reviews. Disease primers · 2024Review
- Serum phosphate level and its kinetic as an early marker of acute kidney injury in tumor lysis syndrome.Journal of nephrology · 2022Article
- A Case of Hemophagocytic Lymphohistiocytosis (HLH) Secondary to T Cell Lymphoma and Cytomegalovirus (CMV) Infection and Complicated by Tumor Lysis Syndrome (TLS).The American journal of case reports · 2022Article
- Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis ofFrontiers in pediatrics · 2022Article
- Article
- Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia.Hematology. American Society of Hematology. Education Program · 2020Article
- Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.Targeted oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
30333933PMC6188097W2774061973What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.